Breast Cancer Liquid Biopsy Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Breast Cancer Liquid Biopsy Market From 2025 To 2034?

The market for breast cancer liquid biopsies has witnessed substantial recent expansion, projected to escalate from a value of $0.78 billion in 2024 to $0.89 billion in 2025, reflecting a compound annual growth rate of 14.2%. This previous period’s upward trajectory is essentially driven by progress in next-generation sequencing technologies, the rising incidence of breast cancer cases globally, an escalating need for diagnostic procedures that do not require invasive sampling, the wider acceptance of tailored medical treatments, and augmented financial support channeled into oncology research initiatives.

Anticipation surrounds the breast cancer liquid biopsy sector, projecting substantial expansion in the immediate future, with its market valuation set to reach $1.53 billion by 2029, expanding at a Compound Annual Growth Rate (CAGR) of 14.5%. This upward trajectory across the projection timeframe stems from several key factors, notably the progress in liquid biopsy assay technologies, a broader incorporation of these biopsies for initial cancer detection, the escalating need for continuous cancer surveillance, wider utilization within personalized cancer treatments, and greater capital allocation towards research and development activities for liquid biopsy solutions. Observably, prevailing currents influencing this market involve weaving artificial intelligence into the interpretation of liquid biopsy data, progress in sequencing methodologies at the single-cell level, creation of comprehensive multi-omics platforms for liquid biopsies, enhancements to the precision and accuracy of these tests, and the embrace of digital PCR techniques for identifying mutations with extremely high resolution.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

What Are The Top Growth Drivers Impacting The Breast Cancer Liquid Biopsy Market Outlook?

Anticipated escalation in the incidence of breast cancer is slated to fuel the expansion of the market for breast cancer liquid biopsies moving ahead. This malignancy, originating within the breast tissues—commonly the milk-producing lobules or the ducts that transport milk towards the nipple—is seeing higher prevalence attributed to various risk elements such as hereditary tendencies, hormonal fluctuations, an aging demographic, shifts in daily habits, elevated body mass, alcohol intake, insufficient exercise, exposure to radiation, and environmental toxins. Liquid biopsies for this condition are employed in treatment protocols to identify cell-free tumor DNA (ctDNA) or circulating tumor cells (CTCs) present in the bloodstream, thus enabling continuous disease surveillance. This technology proves valuable for evaluating how well treatments are working, spotting the emergence of resistance to therapies, and pinpointing specific genetic alterations necessary for selecting personalized treatments. To illustrate this trend, projections from the American Cancer Society, a US organization focused on cancer research, advocacy, education, and patient assistance, indicate that new breast cancer diagnoses are set to climb to 319,750 in 2025 from 313,510 cases noted in 2024. Consequently, this upward trajectory in breast cancer diagnoses serves as a primary impetus for the development of the breast cancer liquid biopsy sector.

What Are The Major Segment Categories Driving The Breast Cancer Liquid Biopsy Market Growth?

The breast cancer liquid biopsymarket covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Which Trends Are Impacting The Breast Cancer Liquid Biopsy Market?

Key participants within the breast cancer liquid biopsy arena are directing their efforts toward creating novel offerings, notably companion diagnostics, with the objective of facilitating customized treatment regimens by distinguishing individuals responsive to particular therapeutic interventions. These companion diagnostics leverage liquid biopsy methodology to pinpoint crucial biomarkers, encompassing genetic alterations, cell-free tumor DNA (ctDNA), or protein signatures that signal potential efficacy of treatment. As an illustration, in the month of January 2023, Guardant Health Inc., a firm based in the United States specializing in biotechnology, secured authorization from the Food and Drug Administration (FDA) for its Guardant360 CDx assay, designating it as a companion diagnostic tool for Menarini Group’s ORSERDU (elacestrant), which addresses advanced or metastatic breast cancer cases harboring ESR1 mutations. This regulatory clearance permits medical professionals administering oncology care to deploy the test for thorough analysis of a patient’s genetic makeup, thus identifying those candidates most likely to gain advantage from this specific targeted medication, simultaneously representing Guardant Health’s inaugural FDA approval within the domain of breast cancer diagnostics in the US and broadening its influence within the field of precision cancer treatment.

Which Industry Leaders Are Driving Innovation Across The Breast Cancer Liquid Biopsy Market?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Breast Cancer Liquid Biopsy Market?

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Breast Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Liquid Biopsy Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Breast Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Breast Cancer Monoclonal Antibodie Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-monoclonal-antibodie-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795